1. Choo Q.-L., Kuo G., Weiner A. J. Isolation of a cDNA clone derived from a blood-bome non-A, non-B viral hepatitis genome. Science. 1989; 244: P. 359 - 362. 2. Волынец Г.В., Панфилова B.H., Жаворонок C.B. Хронические вирусные гепатиты у детей. Учебное пособие. - М.: Издательский Дом ТОНЧУ, 2020. - 376 с. 3. International Committee on Taxonomy of Viruses (ICTV): [https://talk.ictvonline.Org/ictv_wikis/flaviviridae/w/sg_flavi/56/hcv-classification] Обращение 18.11.2020 4. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection.JHepatol 2014;61:S45-57 5. Borgia, S. M., Hedskog, C., Parhy, B., Hyland, R. H., Stamm, L. M., Brainard, D. M., Subramanian, M. G., McHutchison, J. G., Mo, H., Svarovskaia, E. & Shafran, S. D. (2018). Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes. J Infect Dis 2018,1722-1729. 6. Пименов H.H., Чуланов В.П., Комарова C.B. и соавт. Гепатит С в России: эпидемиологическая характеристика и пути совершенствования диагностики и надзора. Эпидемиология и инфекционные болезни. 2012; 3:С. 4 - 9. 7. Жданов К.В., Лобзин Ю. В., Гусев Д.А., Козлов К.В. Вирусные гепатиты. СПб.: Фолиант, 2011. - 304 с. 8. Larrubia J.R., Moreno-Cubero Е., Lokhande M.U., Garcia-Garzon S., Lazaro A., Miquel J., et al. Adaptive immune response during hepatitis C virus infection. World J Gastroenterol. 2014;20(13):3418-30. doi: 10.3748/wjg.v20.il3.3418. 9. Urbani S., Amadei B., Fisicaro P., Tola D., Orlandini A., Sacchelli L., et al. Outcome of acute hepatitis C is related to virusspecific CD4 function and maturation of antiviral memory CD8 responses. Hepatology. 2006; 44:126-39. DOI: 10.1002/ hep.21242 10. Cacoub P., Gragnani L., Comarmond C., Zignego A.L. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46(5): 165-73. doi: 10.1016/j.dld. 2014.10.005 11. Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol 2019; 4: 477-87 12. Nwaohiri, A., Schillie, S., Bulterys, M., & Kourtis, A. P. Towards elimination of hepatitis C virus infection in children. The Lancet Child & Adolescent Health. 2018. 2(4). 235237. doi: 10.1016/s2352-4642(18)30069-5 13. Layden JE, Phillips RO, Owusu-Ofori S, et al. High frequency of active HCV infection among seropositive cases in West Africa and evidence for multiple transmission pathways. Clin Infect Dis 35 2015;60:1033-41 14. WHO. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. [https://apps.who.int/iris/bitstream/handle/l 0665/255016/9789241565455-eng.pdf]. Обращение 18.11.2020 15. Marie-Claude Pelland-Marcotte, Jeremiah Hwee, Jason D. Pole, Paul C. Nathan; Lillian Sung (2019): Incidence of infections after therapy completion in children with acute lymphoblastic leukemia or acute myeloid leukemia: a systematic review of the literature, Leukemia & Lymphoma, DOI: 10.1080/10428194.2019.1573369 16. Губанова M.H., Мадзаев C.P., Жибурт Е.Б. Распространенность и встречаемость инфекций у доноров крови в России./ Вопросы вирусологии. 2015; 60 (5): 29-31. 17. Indolfi G., Nesi A., Resti М. Intrafamilial transmission of hepatitis C virus. J Med Virol. 2013;85(4):608-14. doi: 10.1002/jmv.23522. 18. Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis. 2014;59(6):765- 73. 19. Volynets G.V. et al. Chronic hepatitis C in children in the Russian Federation: a multicenter study. Journal of Hepatology. 2017; V66 (1), 316 - 317. 20. Грешнякова B.A., Горячева Л.Г., Скрипченко H.B. Вирусный гепатит С с перинатальным путем инфицирования: эпидемиология и особенности клинического течения. Педиатрия. 2019; 98 (2): 203-208. 21. Pfaender S, Heyden J, Friesland M, Ciesek W, Ejaz A, Steinmann J, Steinmann J, Malarski A, Stoiber H, Tsiavaliaris G, Bader W, Jahreis G, Pietschmann T, Steinmann E. Inactivation of hepatitis C virus infectivity by human breast milk. The Journal of Infectious Diseases. 2013; 208 (12): 1943- 1952. doi: 10.1093/infdis/jit519. 22. Вирусные гепатиты в Российской Федерации. Аналитический обзор. 11 выпуск / Под ред. В.И. Покровского, А.А. Тотоляна. — СПб.: ФБУН НИИЭМ имени Пастера, 2018. — 112 с. 23.0 состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2019 году: Государственный доклад. -М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2020.-299 с. 24. European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis. 2005;41(l):45- 51. Doi: 10.1086/430601. 25. Jara P., Resti M., Hierro L., Giacchino R., Barbera C., Zancan L., et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis. 2003;36(3):275-80. doi: 10.1086/345908. 26. Indolfi G., Stagi S., Bartolini E., Salti R., de Martino M., Azzari C., et al. Thyroid function and 36 anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clin Endocrinol (Oxf). 2008;68:l 17-21. doi: 10.111 l/j.l365-2265.2007.03009.x. 27. Goodman Z.D., Makhlouf H.R., Liu L., Balistreri W., GonzalezPeralta R.P., Haber B., et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology. 2008;47:836-43. doi: 10.1002/hep.22094. 28. Mohan P., Barton B.A., Narkewicz M.R., Molleston J.P., Gonzalez-Peralta R.P., Rosenthal P., et al. Evaluating progression of liver disease from repeat fiver biopsies in children with chronic hepatitis C: a retrospective study. Hepatology. 2013;58(5): 15801586. doi: 10.1002/hep.26519. 29. Harris H.E., Mieli-Vergani G., Kelly D., Davison S., Gibb D.M., Ramsay M.E. HCV National Register Steering Group. A national sample of individuals who acquired hepatitis C virus infections in childhood or adolescence: risk factors for advanced disease. J.Pediatr Gastroenterol Nutr. 2007;45(3): 335-41. doi: 10.1097/MPG.0b013e3180dc9337 30. Iorio R., Giannattasio A., Sepe A., Terracciano L.M., Vecchione R., Vegnente A. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis. 2005;41(10):1431-7. Doi: 10.1086/497141. 31. Gonzalez-Peralta R.P., Langham M.R. Jr., Andres J.M., Mohan P., Colombani P.M., Alford M.K., et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2009;48(5):630-5. doi: 10.1097/ MPG.0b013e318170af04. 32. Malik S., Dekio F., Wen J.W. Liver transplantation in a child with multifocal hepatocellular carcinoma hepatitis C and management of post-transplant viral recurrence using boceprevir. Pediatr Transplant. 2014;18(2):E64-8. doi: 10.1111/petr.12223 33. Turkova A., Volynets G.V., Crichton S., Skvortsova T.A., Panfilova V.N., Rogozina N.V., et al. Advanced liver disease in Russian children and adolescents with chronic hepatitis C. J Viral Hepat. 2019;26(7):881-892. doi: 10.1111/jvh. 13093. 34. Sun Jl, Yu R, Zhu B, Wu J, Larsen S, Zhao W. Hepatitis C infection and related factors in hemodialysis patients in china: systematic review and meta-analysis. Ren Fail. 2009;31(7):610- 620. 35. Di Napoli A, Pezzotti P, Di Lallo D, Petrosillo N, Trivelloni C, Di Giulio S, Lazio Dialysis Registry: Epidemiology of hepatitis C virus among long-term dialysis patients: A 9-year study in an Italian region. Am J Kidney Dis 2006.- № 48 - P. 629 - 637 36. Xia XI, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health. 2008;122(10):990-1003. 37. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global 37 epidemiology of hepatitis В and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571-583. 38. Price H, Gilson R, Mercey D, et al. Hepatitis C in men who have sex with men in London - a community survey. HIV Med. 2013; 14(9):578-580. 39. Tohme RA, Holmberg S. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology. 2010;52(4): 1497-1505. 40. Санитарно-эпидемиологические правила СП 3.1.3112-13 "Профилактика вирусного гепатита С", утверждены 22 октября 2013 года 41. Leung DH, Squires JE, Jhaveri R, Kerkar N, Lin CH, Mohan P, Murray KF, Gonzalez- Peralta RP, Roberts EA, Sundaram SS. Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper. J Pediatr Gastroenterol Nutr. 2020 Sep;71(3):407-417. doi: 10.1097/MPG.0000000000002814. PMID: 32826718. 42. Kamili S., Drobeniuc J., Araujo A.C. et al. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012;55: S43-S48 43. Smith BD, Yartel AK, Krauskopf K, et al. Hepatitis C virus antibody positivity and predictors among previously undiagnosed adult primary care outpatients: cross-sectional analysis of a multisite retrospective cohort study. Clin Infect Dis. 2015;60(8):l 145-1152. 44. Rein DB, Wagner LD, Brown KA, et al. Current practices of hepatitis C antibody testing and follow-up evaluation in primary care settings: a retrospective study of four large, primary care service centers. Hepatology. 2012;56:1094A. 45. Горячева, Л.Г., Грешнякова, В.А., Рогозина, Н.В., Иванова В.В. Перинатальный вирусный гепатит С и возможности его лечения. Эпидемиология и инфекционные болезни. 2014. № 3. С. 4-8. 46. Tateyama М., Yatsuhashi Н., Тайга N. et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. Gastroenterol. 2011;46:P. 92 - 100. 47. Gebo KA, Chander G, Jenckes MW, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systemic review. Hepatology 2002;36:S84-92. 48. Himoto T., Nishioka M. Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis. Auto Immun Highlights. 2013;4(2):39-53. doi: 10.1007/sl3317- 013-0046- 7. 49. Yang DH, Ho LJ, Lai JH. Useful biomarkers for assessment of hepatitis C virus infectionassociated autoimmune disorders. World J Gastroenterol. 2014; 20: 2962-2970. 50. Инструкция по медицинскому применению препарата “ПегАльтевир” рег.№ per. №: ЛП-002542 от 23.07.2014 38 51. Druyts Е, Thorlund К, Wu Р, et al. Efficacy and Safety of Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in Children and Adolescents: A Systematic Review and Meta-analysis, Clinical Infectious Diseases, Volume 56, Issue 7,1 April 2013, Pages 961-967, 52. El Sherbini A, Mostafa S, Ali E Systematic review with meta-analysis: comparison between therapeutic regimens for paediatric chronic hepatitis С H. Aliment Pharmacol. - Ther. - 2015. - V.42(l). - P. 12-19. 53. Huang CI, Huang CF, Yeh M, et al. Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes. Medicine (Baltimore). 2018;97(10):e9782 54. Alborzi A, Hashempour T, Moayedi F. Role of serum level and genetic variation of IL- 28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients. Med Microbiol Immunol. 2017 Apr;206(2): 165-174. 55. Ea R, Aa G, Ag ES, Ma A. Study of Interleukin 28B rsl2979860 and rs8099917 Polymorphisms and T-helper 1 Response in Hepatitis C Virus Patients. Egypt J Immunol. 2015;22(2):57-68. 56. Olmedo DB, Cader SA, Porto LC. IFN-X gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors. J Med Virol. 2015;87(10): 1702-1715. 57.Jimenez-Sousa MA, Femandez-Rodriguez A, Guzman-Fulgencio M, et al. Metaanalysis: implications of interleukin-28B polymorphisms in spontaneous and treatmentrelated clearance for patients with hepatitis C. BMC Med. 2013; 11:6. 58.Jonas MM, Squires RH, Rhee SM, Lin CW, Bessho K, Feitema-Sperling C, Hierro L, Kelly D, Ling SC, Strokova T, Del Valle-Segarra A, Lovell S, Liu W, Ng TI, Porcalla A, Gonzalez YS, Burroughs M, Sokal E. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study. Hepatology. 2020 Feb;71(2):456-462. doi: 10.1002/hep.30840. 59. Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther. 2019 Jul 29; 13:25652577. doi: 10.2147ZDDDT.S172512. 60. Кулюшина E.A., Ольхова Е.Б. Возможности ультразвукового исследования в диагностике хронических гепатитов и циррозов печени с позиций доказательной медицины. Медицинская визуализация. 2009; 6:С. 122 - 124. 61. Карпова Р.В., Черноусов А.Ф., Хоробрых Т.В. Ультразвуковая диагностика диффузных заболеваний печени. Медицинская визуализация. 2013;2: С. 104-111. 62. Castera L., Vergniol J., Foucher J. et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. 39 Gastroenterology. 2005;128:P.343-350. 63. Павлов Ч.С., Глушенков Д.В., Ивашкин B.T. Современные возможности эластометрии, фибро- и акти- теста в диагностике фиброза печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2008; 28(4): С.43 - 52. 64. Павлов Ч.С., Коновалова О.Н., Глушенков Д.В. и др. Сфера клинического применения неинвазивных методов оценки фиброза печени: результаты собственных исследований в многопрофильном стационаре. Клиническая медицина. 2009;87( 11): С.40 - 44. 65. Павлов Ч.С., Котович М.М. Место биопсии и морфологического исследования ткани печени у детей и взрослых в практике клинициста. Клиническая медицина. 2007;85 (9): С.7-77. 66. Bedossa Р, Poynard Т. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289-293. 67. Tsochatzis EA, Crossan C, Longworth L, et al. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology. 2014;60(3):832-843. 68. Zhang W, Wang L, Wang L, et al. Liver stiffness measurement, better than APRI, Fibroindex, Fib4, and NBI gastroscopy, predicts portal hypertension in patients with cirrhosis. Cell Biochem Biophys. 2015;71(2):865-873. 69. Castera L, Pinzani M, Bosch J. Non invasive evaluation of portal hypertension using transient elastography. J Hepatol. 2012;56(3):696-703. 70. Chen T, Wong R, Wong P, et al. Occult cirrhosis diagnosed by transient elastography is a frequent and under-monitored clinical entity. Liver Int. 2015;35(10):2285-2293. 71. Шерцингер А.Г., Жигалова С.Б., Семенова T.C. и др. Роль эндоскопии в выборе лечения больных портальной гипертензией. Анналы хирургической гепатологии. 2015; 20(2): С. 20- 30. 72. Zhang ВН, Yang ВН, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-422. 73. Vibert E., Azoulay D., Hoti E. et al. Accuracy of ultrasonography, spiral CT, magnetic resonance and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am. J. Gastroenterol., 2006 - № 101 (3) - P. 575-580 74. Трефилов A.A., Карельская H.A., Кармазановский Г.Г. и др. Лучевая диагностика гепатоцеллюлярного рака на фоне цирроза печени. Диагностическая и интервенционная радиология. 2014; 8(2-2): С. 70 - 80. 75. EASL recommendations on treatment of hepatitis C: Final update of the series. Journal of Hepatology 2020 vol. 73 j 1170–1218 76. Panel A-IHG. Hepatitis C Guidance 2018 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2018;67:1477–9277. 40 77. 2018 WHO guidelines for the care and treatment of persons diagnosed with chronic HCV infection, [https://apps.who.int/iris/bitstream/handle/10665/273174/9789241550345- eng.pdf?ua=] Обращение 18.11.2020 78. Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, Rosenthal P, Schwarz KB; North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr. 2012 Jun;54(6):838-55. doi: 10.1097/MPG.0b013e318258328d. PMID: 22487950. 79. Hartwell D., Shepherd J. Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and meta-analysis. Int J Technol Assess Health Care. 2009;25(l):P.56-62. 80. Druyts, E, Thorlund, К, Wu, P, et al. Efficacy and Safety of Pegylated Interferon Alfa-2a or Alfa2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in Children and Adolescents: A Systematic Review and Meta-analysis, Clinical Infectious Diseases, Volume 56, Issue 7,1 April 2013, Pages 961-967, 81. El Sherbini, A., Mostafa, S. and Ali, E. (2015), Systematic review with meta-analysis: comparison between therapeutic regimens for paediatric chronic hepatitis C. Aliment Pharmacol Ther, 42: 12- 19. 82. Schwarz, KB, Gonzalez-Peralta, RP, Murray, KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011; 140: 450- 8. 83. Druyts, E, Thorlund, K, Wu, P, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus Ribavirin for the treatment of chronic Hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis 2013; 56: 961- 7. 84. Jonas, M, Balistreri, W, Gonzalez-Peralta R, et al. Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the Pediatric Study of Hepatitis C (PEDS-C) trial, Hepatology, 2012, vol. 56: 523-31. 85. Горячева, Л.Г., Грешнякова, B.A., Рогозина, H.B., Иванова В.В. Перинатальный вирусный гепатит С и возможности его лечения. Эпидемиология и инфекционные болезни. 2014. № 3. С. 4-8. 86. Лобзин, Ю.В., Горячева, Л.Г., Рогозина, Н.В., Возможности и перспективы лечения хронического гепатита С у детей и взрослых (Обзор литературы). Медицина экстремальных ситуаций. 2015. № 2. С. 8-16. 87. Малышев, Н.А., Чешик, С.Г., Блохина, Н.П., Нурмухаметова, Е.А. «Вирусные гепатиты» (пособие для пациентов), Методические рекомендации N 21. М., 2003. 41 88. Чуелов, С.Б., Россина, А.Л, Учайкин В.Ф., Этиотропная терапия вирусных гепатитов (Обзор литературы). Детские инфекции. 2017. № 3. С. 32-40. 89. Инструкция по медицинскому применению препарата «Мавирет» №: ЛП-004804 от 03.12.2019 90. Инструкция по медицинскому применению препарата «Совальди» №: ЛП-003527 от 04.06.2019. 91. Инструкция по медицинскому применению препарата «Гарвони» №: ЛП-006104 от 19.02.2020 92. Martin NK, Vickerman Р, Dore GJ, et al. Prioritization of HCV treatment in the direct- acting antiviral era: an economic evaluation. J Hepatol 2016;65:17-25. 93. Rein DB, Wittenbom JS, Smith BD, et al. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis 2015;61:157-68. 94. Nguyen J, Barritt ASt, Jhaveri R. Cost Effectiveness of Early Treatment with Direct- Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection. J Pediatr 2019;207:90- 6. 95. Espinosa C, Jhaveri R, Barritt ASt. Unique challenges of hepatitis C in infants, children, and adolescents. Clin Ther 2018;40:1299-307. 96. Younossi ZM, Stepanova M, Henry L, et al. Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens. Medicine (Baltimore) 2016;95:e4151. 97. Slevin AR, Hart MJ, Van Hom C, et al. Hepatitis C virus direct-acting antiviral nonadherence: relationship to sustained virologic response and identification of at-risk patients. J Am Pharm Assoc 2019;59:51-6. 98. Hill AM, Nath S, Simmons B. The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries. J Virus Erad 2017;3:117-23. 99. Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir- sofosbuvir in adolescents 12 to 17 years old with hepatitis C virus genotype 1 infection. Hepatology 2017;66:371-8. 100. Wirth S, Rosenthal P, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology 2017;66:1102-10. 101. Инструкция по медицинскому применению препарата «Эпклюза» №:ЛП- 005703 от 28.10.2020. 102. Leung DH, Wirth S, Yao BB, et al. Ombitasvir/paritaprevir/ritonavir with or without dasabuvir and with or without ribavirin for adolescents with HCV genotype 1 or 4. Hepatol Commun 2018;2:1311-9. 42 103. Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin therapy for children aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection. Hepatology. 2020 Jan;71(l):31-43. doi: 10.1002/hep.30821 104. Jonas M.M., Romero R., Sokal E.M., Rosenthal P., Verucchi G., Lin С.-H., Wen J.W., Narkewicz M.R., Bansal S., Shao J., Hsueh C., Gaggar A., Kersey K., Gonzalez-Peralta R.P., Leung D.H., Balistreri W., Murray K.F., Schwarz K.B. Safety and efficacy of sofosbuvir/velpatasvir in pediatric patients 6 to <18 years old with chronic hepatitis C infection. International liver congress AASLD 2019, Nov 8-12, Boston. Poster#748. 105.Linas BP, Barter DM, Morgan JR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 2015;162:619-29. 106.Aschenbrenner DS. Epclusa Approved For Children With Hepatitis C. Am J Nurs. 2020; 120(7) :26-27. 107.Jonas M.M., Lon H.K., Rhee S., Susan R., Gilmour S.M., Gonzalez-Peralta R.P., et al. Pharmacokinetics of Glecaprevir/Pibrentasvir in children with chronic HCV infection: interim analysis of part 2 of the Dora study. Hepatology, Vol. 74, No. 1, 2021 p.19-27 108.Маевская M. В. Предварительные результаты открытого сравнительного рандомизированного исследования PHG-M3/P01-09 «ОРИОН» по применению препарата «Фосфоглив» в комбинированной терапии больных хроническим гепатитом С. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2011; 21(4): С.52-5 35. 109.Буеверов А.О. Глицирризиновая кислота: патогенетическая терапия хронического гепатита с у особых групп пациентов. Клинические перспективы гастроэнтерологии, гепатологии. 2014. № 4. С. 3-8. 110.Ивашкин В.Т., Маевская М.В., Богомолов П.О., и др. Результаты открытого сравнительного рандомизированного исследования ОРИОН: оценка эффективности отечественных препаратов альтевир и фосфоглив в комбинированной терапии больных хроническим гепатитом С. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2012. Т. 22. № 6. С. 27-37. 111.Tsubota A, Kumada Н, Arase Y, et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. Eur J Gastroenterol Hepatol. 1999;11(10): 1077-83. 112.Chen W, Liu J, Gluud C. Bile acids for viral hepatitis. Cochrane Database Syst Rev. 2007;(4):CD003181 113.Haque TR, Barritt AS 4th. Intestinal microbiota in liver disease. Best Pract Res Clin Gastroenterol. 2016 Feb;30(l): 133-42. doi: 10.1016/j.bpg.2016.02.004. Epub 2016 Feb 9. PMID: 27048904. 43 114.Sehgal R, Bedi O, Trehanpati N. Role of Microbiota in Pathogenesis and Management of Viral Hepatitis. Front Cell Infect Microbiol. 2020 Aug 11; 10:341. doi: 10.3389/fcimb.2020.00341. PMID: 32850467; PMCID: PMC7431464. 115.Woodhouse CA, Patel VC, Singanayagam A, Shawcross DL. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018 Jan;47(2): 192-202. doi: 10.1111/apt.l4397. Epub 2017 Oct 30. PMID: 29083037. 116.Fox RK, Muniraj T. Pharmacologic Therapies in Gastrointestinal Diseases. Med Clin North Am. 2016 Jul;100(4):827-50. doi: 10.1016/j.mcna.2016.03.009. PMID: 27235617. 117.Wang L, Wan YY. The role of gut microbiota in liver disease development and treatment. Liver Res. 2019 Mar;3(l):3-18. doi: 10.1016/j.livres.2019.02.001. Epub 2019 Feb 20. PMID: 32461811; PMCID: PMC7251939. 118.Баранова И.П., Зыкова О.А., Краснова Л.И., Романцов М.Г., Никольская М.В., Афтаева Л.Н. Ремаксол в коррекции нежелательных явлений противовирусной терапии хронического гепатита С. Экспериментальная и клиническая фармакология. 2013. Т. 76. № 11. С. 44-46. 119.Козлов В.К., Стельмах В. В. Применение корректоров клеточного метаболизма и регуляторов и регуляторов энергического обмена клеток в комплексной терапии больных хроническим вирусным гепатитом С (ХВГС). Медицинские новости. 2004. №4 120.Сологуб Т.В., Григорьева Т.Г., Мельникова Г.Ю. и др. Принципы лечения больных хроническими вирусными гепатитами (этапность, индивидуальность, комплексность). Вестник Санкт-Петербургской государственной медицинской академии им. И.И.Мечникова. 2003. № 1-2. С.177-180 121.Архипов Г.И., Исаков В. А., Коваленко А.Л. Влияние реамберина на клиниколабораторные показатели у наркозависимых больных вирусным гепатитом. Лечащий врач. 1999. №10 122.Singh HJ, Singh S, Chander R, Charan S. Comparative study of spironolactone and eplerenone in management of ascites in cirrhosis liver. J Assoc Physicians India. 2016 Jan;64(l):48. 123.Perez-Ayuso RM, Arroyo V, Planas R, et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology. 1983;84(5 Pt 1):961 -8. 124.Santos J, Planas R, Pardo A, et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol. 2003;39(2): 187-92. 125.Черний В.И. Роль и место альбумина в современной инфузионно-трансфузионной терапии. Медицина неотложных состояний. 2017; 1 (80): 23-31 44 126.Shiffman M.L., Salvatore J., Hubbard S. et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007;46:P.371- 379. 127.Pockros P.J., Shiftman M.L., Schiff E.R. et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004;40: P.1450-1458. 128.Sulkowski M.S., Cooper C., Hunyady B. et al. Management of adverse effects of peg- IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8(4):P.212-23. 129.Яковлев A.A., Фирсов С.Л., Опалихина A.B. и др. Гематологические нежелательные эффекты в процессе противовирусной терапии больных хроническим гепатитом С. Клинические перспективы гастроэнтерологии, гепатологии. 2010; 4: С. 19 - 24. 130.Soza A., Everhart J.E., Ghany M.G. et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36:P. 1273-1279. 131.Afdhal NH, Dusheiko GM, Giannini EG,et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology. 2014 Feb;146(2):442-52. 132.Bumess CB. Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis C. Drugs. 2014;74(16):1961-1971. 133.Mihaila RG, Cipaian RC. Eltrombopag in chronic hepatitis C. World J Gastroenterol. 2014;20(35):12517-21. 134.Герасимова О.А. Нехирургические аспекты трансплантации печени: анализ листа ожидания РНЦРХТ в 2000 - 2007 гг. Вестник трансплантологии и искусственных органов. 2008; 5(3): С. 8 - 12. 135.Гранов А.М., Гранов Д.А., Жеребцов Ф.К. и др. Трансплантация печени в РНЦРХТ. Опыт 100 операций. Вестник трансплантологии и искусственных органов. 2012; 14(4): С. 11 - 16. 136.Гранов Д.А., Герасимова О.А., Жеребцов Ф.К. Основные принципы отбора на трансплантацию печени и динамика листа ожидания в ЦНИРРИ (1998 - 2006гг.). Амбулаторная хирургия. Стационарозамещающие технологии. 2007; 2: С. 17 - 19. 137.Хубутия М.Ш., Андрейцева О.И., Журавель С.В. и др. Результаты трансплантации печении в НИИ СП им. Н.В. Склифосовского. Вестник трансплантологии и искусственных органов. 2010; 2: С. 14 - 15. 138.Хубутия М.Ш., Пинчук Т.П., Согрешилин С.С. и др. Эндоскопическое лигирование в остановке и профилактике кровотечении из варикозно расширенных вен пищевода и желудка. Клинические перспективы гастроэнтерологии, гепатологии. 2012; 1: С. 10-15. 139.Шишин К.В., Бакулин И.Г., Недолужко И.Ю. и др. Лигирование варикозно расширенных вен пищевода как метод профилактики кровотечений портального генеза Фарматека. 2016; 45 2: С. 31-35. 140.Lin LL, D SM, Fu Y et al. Combination therapy versus pharmacotherapy, endoscopic variceal ligation, or the transjugular intrahepatic portosystemic shunt alone in the secondary prevention of esophageal variceal bleeding: a meta-analysis of randomized controlled trials., Oncotarget. 2017 May 24;8(34):57399-57408. 141.Dai YP, Gao Q. A prognostic analysis of cirrhotic esophageal variceal bleeding treated with standardized endoscopic therapy. Zhonghua Gan Zang Bing Za Zhi. 2017;25(3): 195-199. 142.Ali SM, Wu S, Xu H, et al. A Prospective Study of Endoscopic Injection Sclerotherapy and Endoscopic Variceal Ligation in the Treatment of Esophageal Varices. J Laparoendosc Adv Surg Tech A. 2017;27(4):333-341 143.Dai C, Liu WX, Jiang M, et al. Endoscopic variceal ligation compared with endoscopic injection sclerotherapy for treatment of esophageal variceal hemorrhage: a meta-analysis. World J Gastroenterol. 2015;21(8):2534-41. 144.Rios Castellanos E, Seron P, Gisbert JP, Bonfill Cosp X. Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension. Cochrane Database Syst Rev. 2015;(5):CD010180. 145.Triantos C, Kalafateli M. Endoscopic treatment of esophageal varices in patients with liver cirrhosis. World J Gastroenterol. 2014;20(36):13015-26. 146.Singhal S, Baikati KK, Jabbour II, Anand S. Management of refractory ascites. Am J Ther. 2012;19(2):121-32 147.Fagiuoli S, Bruno R, Debemardi Venon W et al. Consensus conference on TIPS management: Techniques, indications, contraindications. AISF TIPS Special Conference. Dig Liver Dis. 2017 Feb;49(2): 121-137. 148.Holster IL, Tjwa ET, Moelker A, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ^-blocker for prevention of variceal rebleeding. Hepatology. 2016;63(2):581-9 149.Sauerbruch T, Mengel M, Dollinger M, et al. Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy. Gastroenterology. 2015;149(3):660-8. 150.Xue H, Zhang M, Pang JX, et al. Transjugular intrahepatic portosystemic shunt vs endoscopic therapy in preventing variceal rebleeding. World J Gastroenterol. 2012;18(48):7341-7. 151.Martin N.K., Vickerman P., Foster G.R. et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011 ;54(6):P. 1137-1144. 46 152.Durier N., Nguyen C., White L.J. Treatment of hepatitis C as prevention: a modeling case study in Vietnam. PloS One. 2012;7(4):e34548. 153.Caccamo G, Saffioti F, Raimondo G. Hepatitis В virus and hepatitis C virus dual infection. World J Gastroenterol. 2014 Oct 28;20(40): 14559-67. 154.De Monte A, Couijon J, Anty R et al Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis В virus coinfection as a further challenge. Clin Virol. 2016 May;78:27-30. 155.Wang C, Ji D, Chen J, Shao Q et al. Hepatitis due to Reactivation of Hepatitis В Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents. Clin Gastroenterol Hepatol. 2017 Jan;15(l): 132-136. 156.Эсауленко E.B., Сухорук А.А., Герасимова О. А. и др. Естественное течение хронического гепатита С после трансплантации печени. Инфекционные болезни. 2014;12(1): С.22-27. 157.Сухорук А.А., Эсауленко Е.В., Яковлев А.А. и др.. Эффективность противовирусной терапии рецидива хронического гепатита С у пациентов, перенесших трансплантацию печени. Журнал инфектологии. 2013;5(3): С.35 - 39. 158.Эсауленко Е.В., Герасимова О.А., Сухорук А.А. идр. Опыт противовирусной терапии хронического гепатита С после трансплантации печени. Инфекционные болезни. 2012; 10 (2): С. 84-87. 159.Coilly A., Roche B., Dumortier J. et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014;60:P.78- 86. 160.Kwo P.Y., Mantry P.S., Coakley E. et al. An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. N Engl J Med. 2014; 371:P.2375-2382. 161.Price J.C., Terrault N.A. Treatment of Hepatitis C in Liver Transplant Patients: Interferon OUT, Direct Antiviral Combos IN. Liver Transpl. 2015;21(4):P.423-434. 162.Pungpapong S., Aqel B, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015; 61: P.1880-1886. 163.Kamar N, Marion O, Rostaing L, Cointault O, Ribes D, Lavayssiere L, et al. Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant 2016;16: 1474-1479. 164.D’Ambrosio R, Aghemo A, Rossetti V, Carrinola R, Colombo M. Sofosbuvir based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature. Liver Int. 2016 Nov;36(l 1): 1585-1589. 165.Stallings-Smith S. et al. Long-term follow-up for incident cirrhosis among pediatric cancer survivors with hepatitis C virus infection //Journal of Clinical Virology. – 2015. – Т. 71. – С. 18-21. 47 166.Bedossa, P., Poynard, T., and The METAVIR cooperative study group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996; 24: 289 – 293 167.Инструкция по медицинскому применению препарата «Мавирет», гранулы, покрытые оболочкой, для детей №: ЛП-008048 от 18.04.2022 168. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C https://www.hcvguidelines.org/unique-populations/children, обращение в июне 2022 169.Durand F., Valla D. Assessment of the prognosis of cirrhosis: Child–Pugh versus MELD //Journal of hepatology. – 2005. – Т. 42. – №. 1. – С. S100-S107. 170. Pokorska-Śpiewak M, Dobrzeniecka A, Lipińska M, Tomasik A, Aniszewska M, Marczyńska M. Liver Fibrosis Evaluated With Transient Elastography in 35 Children With Chronic Hepatitis C Virus Infection. Pediatr Infect Dis J. 2021 Feb 1;40(2):103-108. doi:10.1097/INF.0000000000002913. PMID: 33021594. 171.Учайкин B.Ф., Ковалев О.Б. Применение фосфоглива при острых и хронических вирусных гепатитах у детей // Детские инфекции. 2006. №1. 38-43 172.Jones C.R., Flower B.F., Barber E. et al. Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. Wellcome Open Res. 2019 Sep 6;4:132. doi: 10.12688/wellcomeopenres.15411.1. PMID: 31754636; PMCID: PMC6854875.